急诊普通外科抗凝患者:谁出血更多?EAST多中心试验ACES研究
该前瞻性观察性试验纳入2019至2022年21个中心的413例18岁以上、需紧急/急诊普通外科手术且在手术前24小时内使用DOAC或华法林/抗血小板药物的患者。华法林/抗血小板组261例(63%),DOAC组152例(37%)。两组术中、术后及围手术期出血并发症和院内死亡率相似。校正混杂因素后,化疗史(OR 4.3,p=0.015)及手术指征为闭塞性肠系膜缺血(OR 4.27,p=0.016)、非闭塞性肠系膜缺血(OR 3.13,p=0.001)、憩室炎(OR 3.72,p=0.019)与围手术期出血并发症增加相关;术中输血(OR 4.87,p<0.001)和术中血管升压药使用(OR 4.35,p=0.003)与院内死亡率增加相关。作者认为围手术期管理应基于患者生理状态和手术指征,而非近期抗血小板或抗凝药物使用。
要点
- 华法林/抗血小板组与DOAC组的术中、术后及围手术期出血并发症和院内死亡率相似。
- 校正混杂因素后,化疗史与围手术期出血并发症增加相关(OR 4.3,p=0.015)。
- 手术指征为闭塞性肠系膜缺血(OR 4.27,p=0.016)、非闭塞性肠系膜缺血(OR 3.13,p=0.001)、憩室炎(OR 3.72,p=0.019)与围手术期出血并发症增加相关。
- 术中输血(OR 4.87,p<0.001)和术中血管升压药使用(OR 4.35,p=0.003)与院内死亡率增加相关。
- 作者认为围手术期管理应基于患者生理状态和手术指征,而非近期抗血小板或抗凝药物使用。
适用人群与场景
- 18岁或以上,需紧急/急诊普通外科手术,且在需要手术前24小时内使用DOAC或华法林/抗血小板药物的患者。
- 研究于2019年至2022年在21个中心进行。
研究设计与关键结果
- 研究类型:前瞻性观察性试验,2019年至2022年,21个中心,纳入413例患者。
- 华法林/抗血小板组261例(63%),DOAC组152例(37%)。
- 华法林/抗血小板组手术指征以阑尾炎和胆囊炎最常见(43.4% vs. 25%,p=0.001)。
- DOAC组手术指征以小肠梗阻/腹壁疝最常见(44.7% vs. 23.8%,p=0.001)。
- 两组术中、术后及围手术期出血并发症和院内死亡率相似。
- 校正混杂因素后,化疗史与围手术期出血并发症增加相关(OR 4.3,p=0.015)。
- 校正混杂因素后,手术指征为闭塞性肠系膜缺血(OR 4.27,p=0.016)、非闭塞性肠系膜缺血(OR 3.13,p=0.001)、憩室炎(OR 3.72,p=0.019)与围手术期出血并发症增加相关。
- 校正混杂因素后,术中输血(OR 4.87,p<0.001)和术中血管升压药使用(OR 4.35,p=0.003)与院内死亡率增加相关。
证据类型、等级与局限
- 证据类型:前瞻性观察性试验。
- 证据等级:预后与流行病学;Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为围手术期管理应基于患者生理状态和手术指征,而非对近期抗血小板或抗凝药物使用的担忧。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: While direct oral anticoagulant (DOAC) use is increasing in the Emergency General Surgery (EGS) patient population, our understanding of their bleeding risk in the acute setting remains limited. Therefore, the objective of this study was to determine the prevalence of perioperative bleeding complications in patients using DOACs versus warfarin and AP therapy requiring urgent/emergent EGS procedures (EGSPs).
METHODS: This was a prospective observational trial, conducted between 2019 and 2022, across 21 centers. Inclusion criteria were 18 years or older, DOAC, warfarin/AP use within 24 hours of requiring an urgent/emergent EGSP. Demographics, preoperative, intraoperative, and postoperative data were collected. ANOVA, χ 2 , and multivariable regression models were used to conduct the analysis.
RESULTS: Of the 413 patients enrolled in the study, 261 (63%) reported warfarin/AP use and 152 (37%) reported DOAC use. Appendicitis and cholecystitis were the most frequent indication for operative intervention in the warfarin/AP group (43.4% vs. 25%, p = 0.001). Small bowel obstruction/abdominal wall hernias were the main indication for operative intervention in the DOAC group (44.7% vs. 23.8%, p = 0.001). Intraoperative, postoperative, and perioperative bleeding complications and in-hospital mortality were similar between the two groups. After adjusting for confounders, a history of chemotherapy (odds ratio [OR], 4.3; p = 0.015) and indication for operative intervention including occlusive mesenteric ischemia (OR, 4.27; p = 0.016), nonocclusive mesenteric ischemia (OR, 3.13; p = 0.001), and diverticulitis (OR, 3.72; p = 0.019) were associated with increased perioperative bleeding complications. The need for an intraoperative transfusion (OR, 4.87; p < 0.001), and intraoperative vasopressors (OR, 4.35; p = 0.003) were associated with increased in-hospital mortality.
CONCLUSION: Perioperative bleeding complications and mortality are impacted by the indication for EGSPs and patient's severity of illness rather than a history of DOAC or warfarin/AP use. Therefore, perioperative management should be guided by patient physiology and indication for surgery rather than the concern for recent antiplatelet or anticoagulant use.
LEVEL OF EVIDENCE: Prognostic and Epidemiologic; Level III.
参考来源
- O'Meara L, Zhang A, Baum JN, et al. Anticoagulation in emergency general surgery: Who bleeds more? The EAST multicenter trials ACES study. J Trauma Acute Care Surg. 2023. PMID: 37349868. doi:10.1097/TA.0000000000004042
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。